1. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness
- Author
-
Flavia Sorbi, Tania Gamberi, Giovanni Chiappetta, Alessandra Modesti, Tania Fiaschi, Francesca Magherini, Spectrométrie de Masse Biologique et Protéomique (USR3149 / FRE2032) (SMBP), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Proteasome Inhibition ,[SDV]Life Sciences [q-bio] ,Drug Resistance ,Drug resistance ,Pharmacology ,0302 clinical medicine ,Neoplasms ,Drug Discovery ,Auranofin ,cancer ,drug resistance ,NF-kB inhibition ,proteasome inhibition ,thioredoxin reductase inhibition ,5-fluorouracil ,ATRA ,media_common ,all-trans-retinoic acid ,0303 health sciences ,17-Allylamino-17-demethoxygeldanamycin ,auranofin ,AAL ,Protein kinase C iota ,serine/threonine kinase 1 ,3. Good health ,Drug repositioning ,030220 oncology & carcinogenesis ,Molecular Medicine ,medicine.drug ,2-deoxy-D-glucose ,Drug ,Thioredoxin-Disulfide Reductase ,adenanthin ,media_common.quotation_subject ,acute Promyelocytic Leukemia ,Antineoplastic Agents ,acute lymphoblastic leukemia ,ANXA5 ,03 medical and health sciences ,In vivo ,medicine ,Humans ,5-FU ,030304 developmental biology ,17AAG ,business.industry ,AKT ,Cancer ,annexin A5 ,AF ,medicine.disease ,2-DG ,APL ,business ,ADE - Abstract
Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several interesting targets and effects of Auranofin besides the already well-known inhibition of thioredoxin reductase. Among these targets, inhibitory-κB kinase, deubiquitinates, protein kinase C iota have been frequently suggested. To rationalize the effects of Auranofin by a system biology-like approach, we exploited transcriptomic data obtained from a wide range of cell models, extrapolating the data deposited in the Connectivity Maps website and we attempted to provide a general conclusion and discussed the major points that need further investigation.
- Published
- 2021
- Full Text
- View/download PDF